KST 2818

Drug Profile

KST 2818

Latest Information Update: 08 Apr 2008

Price : $50

At a glance

  • Originator Kaneka
  • Class Neuroprotectants; Nootropics; Pyrrolidines; Small molecules
  • Mechanism of Action Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 26 May 2001 Profile reviewed but no significant changes made
  • 25 Aug 1998 No-Development-Reported for Cognition disorders in Japan (Unknown route)
  • 17 Jul 1996 Preclinical development for Cognition disorders in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top